About Biosignatures
The problem we solve
25 years ago, GPs had just 2 blood tests they could use to see if a patient had cancer. Today, despite billions of pounds spent on medical research, they still only have those 2 tests. Biosignatures has solved the problems in life science research that caused this issue.
What we do
Biosignatures discovers new blood tests. Over 10 years, the company has developed a patented machine learning software technology which, combined with the company’s powerful sample measurement system is a disruptive, dramatically cost-effective step forward in the discovery of new clinical diagnostic tests.
Our first product
The company’s first product is a blood test for prostate cancer discovered with the UK’s NHS. In its first independently blinded validation trial it performed 4 times better than current clinical practice. It also holds great promise for wider application as a screen for the disease.
Our potential
In 2019 we will be embarking on a major project to analyse thousands of biobank samples, looking to build novel diagnostic screening tests. Biosignatures’ calculations suggest that existing biobanks are large enough to enable the company’s technologies to reliably generate 20 valuable diagnostic screens. For example - over 4,000 patients in the UKBiobank had no prostate cancer diagnosis when sampled but went onto to be diagnosed with the disease later.
The market opportunity
It is safe to say that if we can deliver on this vision - as we believe we can - it will be transformative for healthcare delivery world-wide. This is especially true for markets where genetic differences in populations mean that tests developed specifically for other populations may not work well. Developing tests for these markets plays perfectly to the company’s capabilities.
A team with a track record
Biosignatures’ management team has a strong background in technology companies including having founded, built and sold Nonlinear Dynamics Ltd.